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p  ! 0.01). In group 1 significantly less Gleason score  6 7
(p = 0.04) and significantly more potentially insignificant 
cancers (p = 0.03) were identified. In 80 patients who subse-
quently underwent radical prostatectomy, final pathology 
revealed no significant differences between the two PSA 
groups with regard to high pT stages, Gleason score  6 7 PCA 
or positive surgical margins, respectively. The difference in 
the absolute risk of being diagnosed with high-grade PCA 
between a PSA threshold of 2.5 ng/ml and a PSA threshold 
of 4 ng/ml was 1%.  Conclusion: Lowering the PSA threshold 
for prostate biopsy from 4 to 2.5 ng/ml results in a substan-
tial increase in the number of men who undergo biopsy and 
may result in an increased detection of potentially insignifi-
cant cancers. If total PSA alone is used to determine the need 
for prostate biopsy, the disadvantages of this lower thresh-
old probably outweigh its potential benefits. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Over the last decade many centers have lowered their 
prostate-specific antigen (PSA) threshold for prostate bi-
opsy to  ! 4 ng/ml in order to detect more prostate cancers 
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 Abstract 
 Objective: In 1999 we lowered the prostate-specific antigen 
(PSA) threshold for prostate biopsy at our institution from 4 
to 2.5 ng/ml. The aim of this study was to compare the dif-
ferences in tumor characteristics of the detected prostate 
cancers (PCAs) and the detection rate for the two different 
PSA thresholds and to evaluate if lowering the threshold was 
justified by any of the detected differences.  Patients and 
Methods: We retrospectively analyzed the records of all pa-
tients who underwent an 8-core prostate biopsy between 
January 1999 and December 2004 and had a PSA between 
2.5 and 10 ng/ml. Patients with a PSA between 2.5 and 4 ng/
ml (group 1, n = 214, mean age 62.0 years) were compared to 
patients whose PSA was between 4 and 10 ng/ml (group 2, 
n = 292, mean age 63.2 years). Patients who were older than 
75 years or had a suspicious rectal examination were exclud-
ed from this study.  Results: Overall, we detected 120 can -
cers in 506 patients (cancer yield 23.7%) .  The cancer yield in 
group 1 was significantly lower than in group 2 (17 vs. 28%, 
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(PCAs) at an organ-confined stage and thus possibly to 
improve cure rates  [1, 2] . This measure, however, increas-
es the number of men undergoing prostate biopsies sub-
stantially. The majority of these men are unnecessarily 
exposed to the morbidity and anxiety associated with the 
procedure  [3] . Additionally, lowering PSA thresholds 
may lead to the detection of more clinically insignificant 
cancers and may further accentuate the problem of over-
treatment  [4, 5] . On the other hand, there is a debate 
whether PSA at low values even correlates with the risk 
of PCA  [6] . Therefore, the optimal PSA cut-off to prompt 
a prostate biopsy, as well as a variety of other parameters 
to improve the performance of the PSA test, are of con-
siderable current interest  [7, 8] .
 In 1999 we lowered the PSA threshold for prostate bi-
opsy at our institution from 4 to 2.5 ng/ml. The aims of 
the present analysis were: (1) to compare the differences 
in the tumor characteristics of the detected PCAs be-
tween the different PSA thresholds and (2) to report the 
differences in cancer detection rate and thus to estimate 
the number of men needed to biopt to detect additional 
high-grade PCA in the PSA range 2.5–4 ng/ml.
 Patients and Methods 
 We retrospectively analyzed the records of all patients who 
underwent an 8-core transrectal ultrasound-guided prostate bi-
opsy in our department between January 1999 and December 
2004. Our patients are typically men from a non-PSA-screened 
population. They were either referred to our department specifi-
cally for a prostate check-up that included a PSA test or had their 
PSA tested after informed consent during a urologic evaluation 
for other causes. For the purpose of this study we excluded pa-
tients who were older than 75 years and patients with a PSA value 
 1 10 or  ! 2.5 ng/ml. Similarly, we excluded patients with a suspi-
cious rectal examination because they would have undergone a 
prostate biopsy regardless of their PSA. In case we detected no 
PCA in the initial biopsy we routinely repeated the prostate bi-
opsy after 4–6 weeks. We defined two groups of men according 
to the PSA value that triggered the first biopsy: men with a PSA 
between 2.5 and 4.0 ng/ml (group 1) and men with a PSA between 
4 and 10 ng/ml (group 2).
 We used the following five definitions throughout the analy-
ses: (1) Patients with a positive (first or second) biopsy were clas-
sified as cancer-positive and patients with two consecutive nega-
tive biopsies were classified as cancer-negative. (2) Patients who 
were cancer-negative after the first biopsy and had no second bi-
opsy were not end-classified for their cancer status and excluded 
from analysis of cancer-related outcomes ( fig. 1 ). We compared 
patient variables of men who were not end-classified with men 
who were end-classified for their cancer status. (3) Potentially in-
significant cancers were defined according to the pretreatment 
criteria of Carter et al.  [9] to predict the presence of small-volume 
cancers. (4) High-grade PCA was defined as Gleason score  6 7 
cancer. (5) Low pT categories were defined as pT2a–c, and ad-
vanced categories from pT3a upwards.
 We compared the two patient groups for the total cancer yield, 
biopsy Gleason scores, and cancer volume in biopsy cores (more 
versus less than 50% cancer per biopsy core). In patients who un-
derwent radical prostatectomy, we additionally compared the two 
groups with regard to positive surgical margins, final Gleason 
score, and pT staging.  To test for differences between groups we 
used the t test for continuous variables and either the   2 test or
the Fisher’s exact test for categorical variables. We used logistic 
regression models to assess: (1) the association between cancer 
(dependent variable, yes/no) and PSA level with adjustment for 
age and prostate volume; (2) the association between Gleason 
score  6 7 cancers (dependent variable, yes/no) and PSA level with 
adjustment for age; (3) the association between potentially insig-
nificant cancers (dependent variable, yes/no) and PSA level with 
adjustment for age.  Statistical analyses were performed using 
SPSS version 12.0.1 (SPSS, Inc., Chicago, Ill., USA).
 Results 
 A total of 506 patients met the inclusion criteria and 
the results of 798 prostate biopsies that were performed 
on these patients could be analyzed. Group 1 (PSA 2.5–
4 ng/ml) consisted of 214 patients and group 2 (PSA 4–
10 ng/ml) consisted of 292 patients. The median age was 
63 years (range 43–75); patient characteristics are sum-
marized in  table 1 . We detected 120 cancers in 506 pa-
tients, accounting for an overall cancer yield of 23.7% 
whereas the cancer yield for the first and second biopsy 
was 17.8 and 10.3%, respectively. There was no significant 
difference with respect to distribution of age categories 
Group 1
PSA 2.5–4 ng/ml
Group 2
PSA 4–10 ng/ml
p value
Number of patients 214 292
Mean age (SD, range) 62.0 (6.7, 44–75) 63.2 (6.9, 43–75) 0.05
Mean PSA (range) 3.2 (2.5–3.98) 6.1 (4.0–9.82) <0.01
Mean prostate volume (range) 32.8 (13–100) 43.8 (13–300) <0.01
Table 1. Characteristics of men 
undergoing prostate biopsy by 
preinterventional PSA
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or PSA categories at first biopsy between patients without 
cancer end classification (n = 124) and patients with can-
cer end classification (n = 382).
 The cancer yield was significantly lower in group 1 
than in group 2 (17 vs. 28%, RR = 0.61, 95% CI = 0.43–
0.86, p  ! 0.01). In the lower PSA group significantly less 
high-grade PCAs were detected than in the higher PSA 
group (p = 0.04). However, significantly more potentially 
insignificant cancers were identified in the lower PSA 
group (p = 0.03). Further characteristics of the detected 
PCAs in the two PSA groups are shown in  table 2 .
 In the 80 patients who subsequently underwent radi-
cal prostatectomy, final pathology revealed no significant 
differences between the two PSA groups with regard to 
the percentage of high pT categories, the percentage of 
patients with high-grade PCA or the percentage of pa-
tients with a positive surgical margin ( table 3 ).
 A logistic regression model restricted to the 382 pa-
tients who were end-classified with regard to their cancer 
status showed a significant positive association between 
cancer and higher PSA levels with an age- and prostate 
volume-adjusted odds ratio of 1.14 (95% CI = 1.00–1.31) 
per 1 ng/ml increase in PSA. Odds ratios to detect poten-
tially insignificant cancer and high-grade PCA in group 
1 relative to group 2 were 2.55 (95% CI = 0.60–10.9, p = 
0.21) and 0.24 (95% CI = 0.08–0.71, p = 0.01), respectively.
506 men undergoing a
first prostate biopsy 
90 men with
prostate cancer  
30 men with
prostate cancer 
120 men with
diagnosed prostate  
124 men without
second biopsy 
292 men undergoing a
second prostate biopsy 
262 men without prostate
cancer after 2 biopsies 
416 men without prostate
cancer after 1 biopsy 
 Fig. 1. Study flow. 
Table 2. Pathological characteristics of biopsy-detected PCA in the two PSA groups
Group 1 
PSA 2.5–4 ng/ml
Group 2
PSA 4–10 ng/ml
Relative risk
(group 1 vs. group 2)
(95% CI; p value)
Number of patients 214 292
Cancer yield (%) 37/214 (17) 83/292 (28) 0.61 (0.43–0.86; p < 0.01)
Cancer volume in biopsy cores ≥50% (%) 2/37 (5.4) 9/83 (10.8) 0.50 (0.11–2.20; p = 0.5)
Gleason score ≥7 (%) 4/37 (10.8) 24/83 (28.9) 0.37 (0.14–1.00; p = 0.04)
Potentially insignificant cancers1 5/24 (20.8) 3/69 (4.3) 4.79 (1.24–18.6; p = 0.03)
1 Pretreatment criteria completely available for 93 patients with PCA (24 patients in group 1 and 69 patients in group 2).
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 With a PSA threshold of 4 ng/ml, 24 out of 382 patients 
(6.3%) were identified with high-grade PCA. By lowering 
the threshold to 2.5 ng/ml, an additional 4 patients were 
detected for a total of 28 out of 382 patients (7.3%). This 
results in an absolute risk difference of 1% between the 
two thresholds. This difference was found to be statisti-
cally insignificant in our study population (95% CI = –2.5 
to 4.6%).
 Discussion 
 The positive association between rising PSA values 
and PCA detection that we found in our study is in ac-
cordance with the data from the first screening round of 
the European Randomized Study of Screening for Pros-
tate Cancer (ERSPC) and with the Prostate Cancer Pre-
vention Trial (PCPT)  [10–12] . In both studies, rising PSA 
was positively associated with the risk of cancer detec-
tion. In contrast to the ERSPC trial, however, our study 
population reflects a referral population rather than a 
screening population; this fact may limit the generaliz-
ability of our results to some extent.
 One objective of our study was to determine differ-
ences in cancer characteristics between the higher and 
the lower PSA group. In our series and in others, between 
11 and 27% of PCAs with a PSA value between 2.5 and
4 ng/ml are high grade (Gleason score  6 7)  [13–15] . There-
fore, there is no PSA threshold able to differentiate be-
tween clinically significant and insignificant PCAs with 
both high sensitivity and high specificity  [11, 13, 15] . In 
our retrospective analysis, men with a PSA between 2.5 
and 4 ng/ml had a statistically significantly decreased 
risk of being diagnosed with high-grade PCA compared 
to men with a PSA of 4–10 ng/ml. However, men in the 
lower PSA group were also more likely to have potential-
ly insignificant tumors.
 Our results confirm that in lower PSA ranges PCAs 
with more favorable pathological features (i.e. Gleason 
score  ^  6, less cancer volume in biopsy cores) are diag-
nosed, which is in line with published data  [1, 2, 15–17] . 
In a recently published study, Makarov et al.  [15] found 
more favorable pathological parameters among men who 
underwent radical prostatectomy at low PSA (2.5–4 ng/
ml) compared to men with a PSA between 4 and 6 ng/ml. 
However, in the same study a trend towards improved 
recurrence-free survival for the low PSA group did not 
reach statistical significance in a total of more than 1,500 
patients. So far there is no convincing evidence in the
literature that lowering the PSA threshold for biopsy to 
 ! 4 ng/ml will lead to an increased biochemical recur-
rence-free survival rate or even a better cancer-specific 
survival rate.
 Moreover, there is concern that lowering the PSA 
threshold for prostate biopsy will lead to overtreatment 
of PCA patients. After lowering the PSA threshold at our 
institution, we identified more patients harboring poten-
tially insignificant PCAs. Even though expectant man-
agement is an acknowledged treatment option for these 
patients, once a PCA is detected, many of them will opt 
for immediate curative treatment  [18–20] . Additionally, 
in patients who subsequently underwent radical prosta-
tectomy, final pathology revealed no significant differ-
ences between the two groups with regard to high Glea-
son scores, extraprostatic disease or positive surgical 
margins.
 In contrast to most other studies which evaluated the 
performance of a PSA threshold  ! 4 ng/ml, we primarily 
analyzed patients who underwent biopsy, not patients 
who underwent radical prostatectomy. We looked only at 
patients with a PSA between 2.5 and 10 ng/ml and a non-
suspicious rectal examination. In this cohort we found 
the absolute risk difference of being diagnosed with high-
grade PCA only to be 1% between a PSA threshold of 2.5 
versus 4 ng/ml. This absolute risk difference implies that, 
compared with the lower PSA threshold, 100 men need 
to undergo prostate biopsy in order to find 1 additional 
patient with high-grade disease. The majority of patients 
Group 1 
PSA 2.5–4 ng/ml
Group 2
PSA 4–10 ng/ml
p value
Number of patients 27 53
Gleason score ≥7, n (%) 7 (25.9) 20 (37.7) 0.33
≥pT3, n (%) 2 (7.7)* 5 (9.4) 0.99
Positive surgical margins, n (%) 4 (14.8) 7 (13.5)** 0.99
Data available for 26 patients (*) and 52 patients (**).
Table 3. Tumor characteristics of men
undergoing radical prostatectomy
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with high-grade PCA (Gleason score  6 7) are still ame-
nable to curative treatment at a PSA level of 4 ng/ml. It is 
therefore conceivable that the number of men needed to 
biopt at a PSA level of 2.5 ng/ml in order to find 1 patient 
that would lose the opportunity for cure by waiting for 
the PSA to rise to 4 ng/ml is still considerably higher than 
100. These facts make us believe that lowering the PSA 
threshold for prostate biopsy from 4 to 2.5 ng/ml is not 
justified.
 Our study has several limitations. No data concerning 
tumor volume in the prostatectomy specimens were 
available to determine potentially insignificant or unim-
portant PCAs according to Epstein et al.  [21] or Ohori et 
al.  [22] and to confirm the pretreatment criteria predic-
tive of small insignificant PCA. In addition, pretreatment 
criteria, especially Gleason grading, were not available 
for all patients due to either small tumor volume in the 
biopsy cores or incomplete pathology reports. However, 
the pretreatment criteria predictive of small volume PCA 
were confirmed prospectively by Carter et al.  [9] and are 
an accepted instrument to predict the presence of such 
tumors. We did not chose more contemporary nomo-
grams like from Nakanishi et al.  [23] or Steyerberg et al. 
 [24]  to predict indolent or potentially insignificant PCA 
because data on tumor length in biopsy cores were lack-
ing very frequently. However, so far no consensus has 
been reached which criteria should be applied to reliably 
predict clinically insignificant or indolent cancer. Fur-
thermore, we do not present follow-up data of treated pa-
tients. Therefore, no statement concerning progression-
free survival rates for the two different PSA threshold 
values is possible. The absolute number of detected and 
subsequently treated PCAs is rather small, especially the 
absolute numbers for Gleason score  6 7 PCA and poten-
tially insignificant cancers. Therefore, our results could 
be underpowered to detect statistically significant differ-
ences in tumor characteristics in the prostatectomy spec-
imens between the two PSA groups. However, our analy-
sis is based on 506 men undergoing 798 prostate biopsies 
and we doubt that differences we were not able to detect 
are clinically important. A further potential confound-
ing factor of the results is the lack that additional param-
eters such as a family history or PSA kinetics were not 
taken into account for biopsy decision-making. Recent 
evidence suggests that PSA velocity adds important in-
formation to identify high-risk PCA already in the pre-
treatment setting  [25] . Hence, a recently published survey 
confirmed that more than 50% of surveyed urologists 
consider PSA velocity an important parameter to indi-
cate a prostate biopsy  [26] .
 We are well aware that the presented data will not set-
tle the dispute over the optimal PSA threshold for pros-
tate biopsy. Proponents of lower PSA thresholds might 
argue that as long as otherwise healthy men are dying 
from PCA, there is no overtreatment and that any num-
ber of biopsies is justified in order to detect more PCA at 
a potentially curable stage  [27] . Based on our results, 
however, we do not support the notion that simply lower-
ing the PSA threshold for biopsy  ! 4 ng/ml will lead to the 
detection of a significant amount of curable cancers 
which would be incurable at a PSA of 4 ng/ml. Hopefully, 
in the future, additional markers and further parameters 
like PSA velocity will potentially lead to a more tailored 
use of prostate biopsies and will ideally improve the diag-
nostic yield of this invasive test.
 Conclusion 
 Lowering the PSA threshold for prostate biopsy from 
4 to 2.5 ng/ml results in a substantial increase in the num-
ber of men who undergo biopsy and may result in an in-
creased detection of potentially insignificant cancers. If 
total PSA alone is used to determine the need for prostate 
biopsy, the disadvantages of this lower threshold proba-
bly outweigh its potential benefits.
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